Patent application number | Description | Published |
20100081142 | BIOMARKERS FOR KIDNEY DISEASES AND METHOD FOR USING SAME - The present invention provides biomarkers for detecting kidney disease, selected from the oligonucleotide sequence, complementary sequence or derivatives, amino acid sequence or derivatives, fragment, variants, antibody of annexin A2 or S100A6 or combinations thereof. Moreover, the present invention also provides an assay kit and a method for kidney disease detecting, practically for the kidney disease resulting from acute tubular necrosis. | 04-01-2010 |
20110183349 | BIOMARKERS FOR IgA NEPHROPATHY AND APPLICATIONS THEREOF - The present invention provides a method for diagnosis or prognosis of IgA nephropathy in a subject based on detection of the expression level of one or more biomarker genes selected from the group consisting of thymosin β4 (Tmsb4), serine or cysteine proteinase inhibitor clade E member 2 (Serpine2), secreted phosphoprotein 1 (OPN), butyrophilin-like-2 (BTNL2), S100 calcium binding protein A8 (S100A8), Cystatin C (CysC), and any combination thereof. | 07-28-2011 |
20120129175 | METHOD FOR RENAL DISEASE DIAGNOSIS AND PROGNOSIS USING ANNEXIN A1 AND RAB23 AS MARKERS - Use of Annexin A1 or Rab23 as a biomarker for diagnosing kidney disease or assessing efficacy of kidney disease treatment. | 05-24-2012 |
20120189719 | SCHISANDRAE FRUCTUS EXTRACTS FOR INHIBITION OR PREVENTION OF H1N1 INFLUENZA VIRUS INFECTION AND ITS APPLICATION THEREOF - Disclosed are an Schisandrae fructus extract for inhibition or prevention of influenza and its application, wherein the Schisandrae fructus extract is obtained by water, methanol, or ethanol extraction process and the extract comprises compounds such as schisandrone, benzoylgomisin P, wulignan A1, epigomisin O, epiwulignan A1, and tigloylgomisin P. The extracts and purified compounds of Schisandrae fructus has anti-influenza virus H1N1 and H1N1-TR (a Tamiflu drug resistant virus strain) activities, therefore the extracts and the purified compounds of Schisandrae fructus can be applied as an inhitibory agent of a pharmaceutical composition for treatment or prevention agent for influenza infection. | 07-26-2012 |
20120196287 | Tmsb4 as a Biomarker for IgA Nephropathy - The present invention provides a method for diagnosis or prognosis of IgA nephropathy in a subject based on detection of the expression level of one or more biomarker genes selected from the group consisting of thymosin β4 (Tmsb4), serine or cysteine proteinase inhibitor clade E member 2 (Serpine2), secreted phosphoprotein 1 (OPN), butyrophilin-like-2 (BTNL2), S100 calcium binding protein A8 (S100A8), Cystatin C (CysC), and any combination thereof. | 08-02-2012 |
20120309821 | Use of epigallocatechin-3-gallate for immune regulation - The preset invention relates to a method for treating lupus erythematosus, particularly lupus nephritis, comprising administering a subject in need thereof a therapeutically effective amount of epigallocatechin-3-gallate (EGCG) or a pharmaceutically acceptable salt or a physiologically functional derivative, together with one or more pharmaceutically acceptable carriers, diluents or excipients. | 12-06-2012 |
20130101998 | METHOD FOR DIAGNOSING KIDNEY DISEASE COMPRISING DETECTING THE LEVEL OF ANNEXIN A2 OR S100A6 - The present invention provides biomarkers for detecting kidney disease, selected from the oligonucleotide sequence, complementary sequence or derivatives, amino acid sequence or derivatives, fragment, variants, antibody of annexin A2 or S100A6 or combinations thereof. Moreover, the present invention also provides an assay kit and a method for kidney disease detecting, practically for the kidney disease resulting from acute tubular necrosis. | 04-25-2013 |
20130323750 | Method for Analyzing Apoptosis Inducing Factor-2 - A method for analyzing apoptosis inducing factor-2 (AIF-2) is disclosed, which has not been found in urine samples of human patients with chronic kidney disease, to establish AIF-2 as a non-invasive biomarker for chronic kidney disease. The method includes: collecting a plurality of urine samples; conducting western blot for each urine sample for detecting the AIF-2 protein content in each urine sample; and conducting statistical analysis of the AIF-2 protein content in each urine sample to establish AIF-2 as a biological marker for chronic kidney disease. | 12-05-2013 |